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Reducing Bias from Test Misclassification in Burden of Disease Studies: 
Use of Test to Actual Positive Ratio – New Test Parameter
Aim To address the problem of estimating disease frequency identified by a 
diagnostic test, which may not represent the actual number of persons with 
disease in a community, but rather the number of persons who tested positive. 
Those two values may be very different, their relationship depending on the 
properties of the diagnostic test applied and true prevalence of the disease in 
a population.
Methods We defined a new test parameter, the ratio of Test to Actual Posi-
tives (TAP), which summarizes the properties of the diagnostic test applied 
and true prevalence of the disease in a population, and propose that is the 
most useful summary measure of the potential for bias in disease frequency 
estimates.
Results A consideration of the relationship between the sensitivity (Se) and 
specificity (Sp) of the diagnostic test and the true prevalence of disease in a 
population can inform study design by highlighting the potential for disease 
misclassification bias. The effects of a decrease in Sp on the TAP ratio at very 
low disease prevalence are dramatic, as at 80% Sp (and any Se value including 
100%), the measured disease frequency will represent a 25-fold overestimate. 
At a disease prevalence of 0.10, the Sp needs to be 90% or greater to achieve a 
TAP ratio of 1.0. However, unlike at lower levels of disease prevalence, the test 
Se is also an important determinant of the TAP ratio. A TAP ratio of 1.0 can 
be achieved by a Sp of 95% and intermediate Se (40%-60%); or a Sp of 99% 
and very high Se (over 90%). This illustrates how a test with poor performance 
characteristics in a clinical setting can perform well in a disease burden study 
in a population. In circumstances in which the TAP ratio suggests a potential 
for a large bias, we suggest correction procedures that limit disease misclas-
sification bias and which are often counter-intuitive. We also illustrate how 
these methods can improve the power of intervention studies, which define 
outcomes by use of a diagnostic test.
Conclusions Optimal screening test characteristics for use in a population-
based survey are likely to be different to those when the test is used in a clinical 
setting. Calibrating the test a priori to bring the TAP ratio closer to unity deals 
with the possible large bias in disease burden estimates based on application of 
diagnostic (screening) test.
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Observational studies estimate burden of 
disease and are increasingly used to inform 
health planning and resource allocation deci-
sions at both the global and local level (1-4). 
However, measures of disease frequency (eg, 
prevalence and incidence) reported in these 
studies typically do not represent the actu-
al number of persons with disease in a com-
munity, rather they show the number of per-
sons who tested positive for a diagnostic test 
(including verbal autopsies). Those two values 
may be very similar, but may also be very dif-
ferent, depending on the properties of the di-
agnostic test applied (5).
Evaluations of diagnostic or screening tests 
within public health programs have concen-
trated on the test parameters – sensitivity (Se) 
and specificity (Sp) – since these describe per-
formance within the overall program. They are 
independent of disease prevalence and thus es-
timates of these parameters in one setting may 
retain relevance in a variety of settings. Eval-
uations of diagnostic tests within clinical set-
tings often focus on positive and negative pre-
dictive values and likelihood ratios of the test, 
as these guide the interpretation of the test to 
individual patients (6). However, in this paper 
we consider a different use of a test, where the 
primary aim is estimating the prevalence or in-
cidence of disease in a population.
In our recent review, which aimed to 
produce global burden estimate of a specif-
ic childhood disease (pneumonia) for the 
World Health Organization (WHO) (7), 
we realized that large potential problems ex-
ist when diagnostic tests designed for use in 
clinical settings are applied in community 
settings to measure disease frequencies (5,8-
10). In this study, we aimed to define the re-
lationships between diagnostic test validity, 
disease prevalence, and accuracy of disease 
frequency estimates. We considered poten-
tial implications of these relationships on 
study design and interpretation and illustrat-
ed these with examples from the literature 
and our own work. We also generalized these 
findings to discuss the impact of an imperfect 
screening or diagnostic test in yielding inac-
curate estimates of disease prevalence and in-
cidence (as well as invalid comparisons across 
groups); and limiting the power of a study to 
detect differences in disease prevalence and 
incidence across groups.
Methods
We used a 2 × 2 table in which “D present” 
and “D absent” represent the true state of pres-
ence or absence of disease (D). “D test posi-
tive” represents all examined cases that tested 
positive on examination with the chosen diag-
nostic test. “D test negative” represents all ex-
amined cases that did not fulfill all the required 
criteria to establish a diagnosis. Definitions of 
sensitivity, specificity, positive predictive val-
ue, negative predictive value, and probability of 
test-positive (T) are given in Table 1.
Published community-based cohort stud-
ies seeking to estimate disease incidence or 
prevalence (especially in regions with limited 
resources) can only measure the number of ex-
aminees who tested positive for disease (a + b) 
as a proxy for the true number of examinees 
with disease (a + c) (7). For the purpose of es-
timating disease frequency, it would be advan-
tageous for the test to be configured in a par-
ticular setting so that (a + b) is approximately 
equal to (a + c), and thus that the number of 
Table 1. Table of distribution of diagnosed cases according to 
diagnostic test result and true disease status*
D present D absent
D test positive “a” “b”
D test negative “c” “d”
*Cell “a” represents examinees with D (true positives) who tested positive; cell “b” 
represents examinees without D (true negatives) who tested positive; cell “c” repre-
sents examinees with D (true positives) who tested negative; and cell “d” represents 
examinees without D (true negatives) who tested negative. Sensitivity of diagnostic 
test is thus generally given by [a/(a + c)]; specificity by [d/(b + d)]; positive predictive 
value by [a/(a + b)]; negative predictive value by [d/(c + d)]; disease prevalence by 
[(a + c)/(a + b+c + d)]; the number of examinees (N) by (a + b+c + d). The probability of a 
test-positive is given by (a + b)/N. The probability of a true positive given by (a + c)/N is 
equivalent to disease prevalence.
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false positives (b) and false negatives (c) were 
equivalent. We considered the parameter 
(a + b)/(a + c), defined as the ratio of the num-
ber of examinees who tested positive to the 
number of examinees with actual disease, and 
designated here as the ratio of Test to Actual 
Positives (TAP):
TAP = (a + b)/(a + c) [1]
For example, if the TAP ratio equals 3 for 
a given test, then the observed incidence or 
prevalence is a 3-fold overestimate of truth 
(Box 1) or alternatively, the TAP ratio is the 
ratio of the probability of test positive to the 
probability of true positive, ie,
TAP = ((a+b)/N)/((a+c)/N),  [2] or al-
ternatively
(a + c)/N.
TAP = T/P [3]
where T is the probability of test positive, 
P is the probability of true positive (or disease 
prevalence), and N is the number of examin-
ees (Table 1).
When estimating disease frequency using 
a screening test, the values (a + b) and (a + c) 
should ideally be equal, resulting in a TAP ra-
tio value of 1.0. When the TAP ratio exceeds 1, 
it represents the amount by which the true dis-
ease frequency in the studied population has 
been overestimated. When less than 1, it is the 
amount by which the true disease frequency in 
the studied population has been underestimated.
The relationships between TAP ratio and 
test sensitivity, specificity, and disease preva-
lence can be derived algebraically. TAP can be 
rewritten in a number of ways, eg, as a func-
tion of Se, Sp, and the typically unknown P:
TAP = [1-Sp-P(1-Sp-Se)]/P [4]
TAP can also be written as a function of 
only the known quantities Se, Sp, and T:
TAP = T(Se+Sp-1)/[T-(1-Sp)] [5]
The TAP ratio will equal 1.0 when:
P = (1-Sp)/[(1-Sp)+(1-Se)] [6]
Any imbalance between the number of 
false positives and false negatives creates inac-
curacy between true cases and test-positives. 
The key condition for the probability of test 
positive (T) to equal the true probability of 
disease (P) is
(1-Sp)/(1-Se) = P/(1-P) [7]
ie, the ratio of the false-positive rate (1-Sp) 
to the false-negative rate (1-Se) should equal 
the true odds of disease. If the false positive/
false negative ratio is greater than the odds 
of disease, then the probability of test posi-
tive will overestimate the true probability of 
disease (t > P); on the other hand, if the false 
positive/false negative ratio is smaller than 
the odds of disease, then the probability of 
test positive will underestimate the true dis-
ease prevalence (t < P). Thus, TAP equals uni-
ty if and only if equation [7] is true. This im-
plies that P can be computed if T and TAP are 
known (ie, P = T/TAP).
From equation [6] it can be seen that at a 
disease prevalence of 50%, specificity will need 
to equal sensitivity to achieve TAP ratio of 
1.0. At any true disease prevalence lower than 
50%, specificity will need to be greater than 
sensitivity.
Finally, the TAP ratio can be expressed in 
terms of sensitivity and positive predictive val-
ue (PPV) of the test, which can be useful in 
some circumstances, as follows:
TAP = Se/PPV [8]
Results
Use of TAP ratio in summarizing the potential 
for disease misclassification bias in disease 
frequency estimates
It is well known that an imperfect test may 
yield a biased estimate of the disease preva-
lence. However, the size of this effect and 
hence the need to limit or correct for this bias 
is not always clearly appreciated. We present 
several examples of diseases with varying point 
prevalences (Boxes 1-5) to demonstrate how 
the properties of a diagnostic test affect the ac-
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curacy of the disease frequency estimate. These 
examples illustrate how the TAP ratio can 
summarize the potential for bias in disease fre-
quency estimates. We have selected examples 
relevant to developing countries and other re-
source-poor areas since the use of a simple di-
agnostic test result without further investiga-
tive confirmation is typical in disease burden 
studies in these settings.
Example 1 (Box 1): Screening for clinical 
pneumonia in children using WHO diagnos-
tic criteria (prevalence = 0.01) Example 1 (Fig-
ure 1) shows that at low disease prevalence of 
0.01 in the population, the specificity of the 
test needs to be very high if measured disease 
frequency is not to be overestimated by one or 
two orders of magnitude. The accuracy of the 
disease frequency estimate relies almost entire-
ly upon test specificity. Sensitivity of the di-
agnostic test is not an important determinant 
of the TAP ratio (at very low disease preva-
lence) and hence the ability of the test to pro-
duce accurate disease estimates. The effects of 
a decrease in test specificity on the TAP ratio 
at very low disease prevalence are dramatic, as 
at 80% specificity (and any sensitivity value in-
cluding 100%), the measured disease frequen-
cy will represent a 25-fold overestimate. Thus, 
when the expected disease frequency is very 
low, a diagnostic test for disease burden esti-
mates should only be employed if positives can 
be checked (see use of positive predictive value 
below).
Example 2 (Box 2). Screening for diabetes 
mellitus using WHO diagnostic criteria (prev-
alence = 0.05). Example 2 (Figure 2) presents 
the relationship between sensitivity, speci-
ficity, and TAP ratio when the disease preva-
lence is 0.05. It can be seen from Figure 2 that 
if small modifications were made to the rec-
ommended WHO test cut-off levels, such that 
test specificity falls to 95% and test sensitiv-
Figure 1. Relationship between test sensitivity, specificity, and Test to 
Actual Positives (TAP) ratio at a disease prevalence of 0.01.
Box 1. Screening for clinical pneumonia in children 
using World Health Organization diagnostic criteria 
(prevalence=0.01)
Pneumonia and bronchiolitis are together one of the most 
important causes of global burden of disease and one of 
the largest causes of death in young children (11). The WHO 
diagnostic test for the assessment of clinical pneumonia in 
young children has been frequently applied to estimate dis-
ease incidence in community-based studies in developing 
countries (7). The test is positive if a child (with a cough or 
difficult breathing) is found to have a raised respiratory rate or 
lower chest wall indrawing. Estimates of clinical pneumonia 
incidence from cohort studies with weekly surveillance fall in 
the range 0.1-0.5 episodes per child-year, with median dura-
tion of clinical pneumonia episode from 1-4 weeks, suggest-
ing a weekly point prevalence of disease between 0.002 and 
0.04 (12). Reported values for the sensitivity and specificity of 
this test fall in the range 40-95% (13,14). Figure 1 shows how 
the properties of this test can affect the incidence estimate 
when the point prevalence of disease in the study population 
is close to 1%. Even at very high test specificity of 99% (and 
regardless of test sensitivity), the Test to Actual Positives ra-
tio will still be about 3.0. This means that the measures of 
incidence resulting from the application of this test are 3-fold 
overestimates.
Box 2. Screening for diabetes mellitus using World 
Health Organization (WHO) diagnostic criteria (preva-
lence=0.05)
Diabetes prevalence is rising in many developing countries 
and the true prevalence in the adult population in many set-
tings is of the order of 5% (15). Figure 2 presents the relation-
ship between sensitivity, specificity, and Test to Actual Posi-
tives (TAP) ratio when the disease prevalence is 0.05. When 
measuring prevalence in population-based studies, investi-
gators frequently use fasting blood glucose, random blood 
glucose or the oral glucose tolerance test. WHO criteria state 
that the diagnosis of diabetes mellitus can be established if 
the value of fasting glucose is greater than 7.8 mmol/L, or 
value after 2 hours is greater or equal 11.1 mmol/L. Yudkin et 
al (16) estimated the sensitivity of the oral glucose tolerance 
test to be 32%, and specificity to be 99%.
The TAP ratio for these values of specificity and sensitivity is 
about 0.5 (Figure 2). Thus, community-based studies of the 
prevalence of diabetes mellitus using oral glucose tolerance 
test and WHO diagnostic criteria will underestimate true dis-
ease frequency by 50%.
Croat Med J 2008;49:402-414
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ity rises, the TAP ratio would move closer to 
1 and thus the test would yield more accurate 
disease frequency estimates. This illustrates 
that the most appropriate test specification is 
not always intuitively obvious. In this exam-
ple, a small reduction of test specificity (and 
consequent small rise in test sensitivity) would 
yield better test performance in a disease bur-
den study.
Example 3 (Box 3). Screening for trichomoni-
asis using Papanicolau Test (prevalence = 0.10). 
Example 3 (Figure 3) shows that at a disease 
prevalence of 0.10, the specificity needs to be 
90% or greater to achieve a TAP ratio of 1.0. 
However, unlike at lower levels of disease prev-
alence, the test sensitivity is also an impor-
tant determinant of the TAP ratio. A TAP ra-
tio of 1.0 can be achieved for example by (a) a 
specificity of 95% and intermediate sensitivity 
(40%-60%) or (b) a specificity of 99% and very 
high sensitivity (over 90%). This example illus-
trates how a test with poor performance char-
acteristics in a clinical setting can perform well 
in a disease burden study. It also shows that a 
combination of very high sensitivity and very 
high specificity is not necessarily the only suit-
able test specification. Figure 4 illustrates the 
relationship at a disease prevalence of 0.20.
Example 4 (Box 4). Screening for tuber-
culosis in HIV-infected persons using Man-
toux, polymerase chain reaction, and amplified 
mycobacterium direct (AMDT) tests (preva-
lence = 0.40). Example 4 (Figure 5) illustrates 
that the most appropriate combination of val-
Figure 2. Relationship between test sensitivity, specificity and Test to 
Actual Positives (TAP) ratio at a disease prevalence of 0.5.
Box 3. Screening for trichomoniasis using Papanicolau 
test (prevalence=0.10)
Trichomonas vaginalis is the most frequent non-viral cause 
of sexually transmitted disease in the world. Its prevalence 
in developing country settings is estimated at about 0.1 
among women of reproductive age (4). In western countries, 
the definitive diagnosis of the disease is established using 
polymerase chain reaction (PCR) technology to detect T. 
vaginalis in cervicovaginal DNA samples using sets of spe-
cific primers. However, in developing countries, the disease 
is detected mainly through the use of the Papanicolau test. A 
recent study validated it on over 1000 cervicovaginal swab 
specimens from a randomized sample of women in Brazil, 
using PCR to confirm true disease status (17). The study 
showed that the sensitivity of the Papanicolau test to detect 
T. vaginalis is 61%, and specificity 98%. Figure 3 shows that 
this screening test, apparently of limited value in clinical set-
ting, would still be excellent for population-based disease 
prevalence estimates (carried out, for example, as part of a 
cervical cancer screening program). At a disease prevalence 
of about 10% in a population, this combination of sensitivity 
and specificity yields Test to Actual Positives ratio of 0.98, 
thus the proportion of infected cases measured by this test 
will very nearly equal the true proportion of infected in the 
population (Figure 3).
Figure 3. Relationship between test sensitivity, specificity, and Test to 
Actual Positives (TAP) ratio at a disease prevalence of 0.1.
Figure 4. Relationship between test sensitivity, specificity, and Test to 
Actual Positives (TAP) ratio at a disease prevalence of 0.2.
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ues of test sensitivity and specificity can be 
counter-intuitive and need special consider-
ation. This may reveal that the use of cheaper 
or more efficient alternative test strategies in 
circumstances where resources are limited may 
be acceptable in disease burden studies. It also 
illustrates that underestimation may be more 
likely at high prevalence, since diagnostic tests 
in developing countries often have moderately 
high specificity and only moderate sensitivity 
yielding a TAP ratio of <1.
Example 5 (Box 5). Screening for iodine de-
ficiency by the rapid urinary iodide test (preva-
lence >0.50). Example 5 illustrates that at a 
high disease prevalence level the magnitude of 
over- or under-estimation is much lower than 
at lower disease prevalence levels (see also ex-
ample 4).
Limiting bias from test misclassification
A preliminary estimate of the TAP ratio in the 
design of a study can be helpful. It may be dif-
ficult to make a precise estimate since this may 
require detailed information on various test 
configurations (ie, how sensitivity and speci-
ficity vary with varying cutpoints or defini-
tions of test criteria) and an accurate estimate 
of the underlying true probability of disease 
before the study is performed. However, even 
a rough estimate of the TAP ratio will help 
identify situations in which there is a very large 
potential for bias, such as in studies of diseases 
in low prevalence (Boxes 1 and 2). This impor-
tant information may suggest the need for an 
alternative diagnostic test (or reconfiguration 
of the test to have a more favorable TAP ra-
tio) or study design or the need to use the di-
rect correction approach described below in 
order to reduce bias in disease frequency esti-
mates. Table 2 provides the combinations of 
test sensitivity and specificity at given values of 
disease prevalence required to yield a TAP ra-
tio of 1.0.
Box 4. Screening for tuberculosis in HIV-infected per-
sons using Mantoux, polymerase chain reaction, and 
amplified mycobacterium direct (AMDT) tests (preva-
lence=0.40)
Tuberculosis disease is a common complication of HIV in 
developing countries. In some countries significant parts of 
entire populations are affected with HIV, and prevalence of 
tuberculosis among HIV-infected adults is about 40% (18). 
Concerns over the validity of the Mantoux test in HIV-infected 
patients has resulted in the investigation of the utility of tests 
based on nucleic amplification for diagnosis of pulmonary tu-
berculosis in resource-poor settings with high prevalence of 
HIV (19). The low-cost one-tube nested PCR test showed a 
sensitivity of 80% and specificity of 40%, which would yield 
a Test to Actual Positives (TAP) ratio of 1.7 (Figure 5), while 
more costly and sophisticated AMDT had a sensitivity of 92% 
and specificity of 60%, which would yield a TAP ratio of 1.5 
(Figure 5).
Figure 5. Relationship between test sensitivity, specificity, and Test 
to Actual Positives (TAP) ratio at a disease prevalence of 0.4.
Box 5. Screening for iodine deficiency by the rapid uri-
nary iodide test (RUIT) (prevalence>0.50)
The situations in which human diseases reach a population 
point prevalence greater than 50% are unusual but several 
examples exist, such as hypertension or cardiovascular dis-
ease among the elderly in European countries (15,20). In 
addition, serious disease risk factors can reach very high 
prevalences in developing countries. One example is iodine 
deficiency, the most common preventable cause of mental 
retardation and brain damage, which has also been associ-
ated with lower mean birth weight, impairment of hearing and 
motor skills, and neurological dysfunction (15). It is estimated 
that more than one-third of the world’s population may be at 
risk of iodine deficiency, so the prevalence in some areas 
of the developing world can be exceptionally high (21). The 
gold standard for identifying iodine deficiency in children is 
by performing the Sandell-Kolthoff reaction in urine speci-
mens. Recently, the performance of a new semi-quantitative 
method, affordable and simple to perform, was assessed in 
a developing country setting (22). The RUIT method showed 
a sensitivity of 96% and a specificity of 61%. At a prevalence 
of iodine deficiency among children of 90% or more, this test 
would have Test to Actual Positives ratio of very close to 1.0. 
However, at a lower true prevalence, eg, of 70% or 50%, the 
test will overestimate prevalence of iodine deficiency in the 
population by 13% and 35%, respectively.
Croat Med J 2008;49:402-414
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Estimating the TAP ratio. As noted above, 
an accurate estimation of the TAP ratio (equa-
tions 2-4 and Figures 1-5) requires that the 
properties of diagnostic test (sensitivity and 
specificity) are established before the study 
and that the expected true prevalence (or in-
cidence) of disease is also known, either from 
previous published studies in same population 
or from studies in similar populations. Typi-
cally, all these data are not available. In these 
circumstances, the TAP ratio can be estimated 
by measuring the test positive predictive val-
ue. This will involve further investigation of 
the cases that were identified as positive by the 
diagnostic test. All, or a random sample of all, 
who tested positive should be referred to local 
hospital or research center, where the diagno-
sis can be confirmed or excluded by physicians 
with more experience, using more sophisticat-
ed and valid diagnostic methods. Dividing the 
sensitivity of the diagnostic test (known from 
published reports or past experience with the 
test before the study is undertaken) by the 
positive predictive value (established through 
this further investigation of those who tested 
positive, which can be performed during the 
study) will yield an estimate of the TAP ratio 
(see equation 8). Alternatively, limits within 
which the TAP ratio must lie can than be de-
fined over a range of plausible test sensitivity 
values.
It is important to note that, whereas Se and 
Sp are more stable across studies at least with-
in levels of disease and covariates such as age, 
sex, and socioeconomic status, PPV values de-
pend heavily on disease prevalence, which var-
ies from study to study. Thus, the use of PPV 
should be limited to studies in which internal 
validation data are available (13,23,24). Figure 
6 shows how the TAP ratio depends on differ-
ent combinations of diagnostic test sensitivity 
and positive predictive value.
Using the TAP ratio to make a direct cor-
rection for bias from test misclassification. From 
above,
P = T/TAP
Once the TAP ratio has been estimated, 
then the disease prevalence can be obtained by 
prevalence = T/TAP or prevalence = number 
of true positives divided by the TAP ratio.
Table 2. Levels of test specificity required for various levels of test sensitivity and disease prevalence to achieve a Test to Actual Posi-
tives (TAP) ratio of 1.0*
Prevalence of disease in a population
Sensitivity 0.01 0.03 0.05 0.10 0.15 0.20 0.25 0.30 0.40 0.50
0.100 0.991 0.972 0.953 0.900 0.841 0.775 0.700 0.614 0.400 0.100
0.200 0.992 0.975 0.958 0.911 0.858 0.800 0.733 0.657 0.466 0.200
0.300 0.993 0.978 0.963 0.922 0.876 0.825 0.766 0.700 0.533 0.300
0.400 0.994 0.981 0.968 0.933 0.894 0.850 0.800 0.743 0.600 0.400
0.500 0.995 0.984 0.973 0.944 0.911 0.875 0.833 0.786 0.666 0.500
0.600 0.996 0.987 0.978 0.955 0.929 0.900 0.866 0.830 0.733 0.600
0.700 0.997 0.990 0.983 0.966 0.947 0.925 0.900 0.872 0.800 0.700
0.800 0.998 0.993 0.988 0.977 0.964 0.950 0.933 0.914 0.866 0.800
0.900 0.999 0.996 0.994 0.988 0.982 0.975 0.966 0.957 0.933 0.900
0.950 1.000 0.998 0.997 0.994 0.991 0.987 0.983 0.979 0.967 0.950
0.990 1.000 0.999 0.999 0.999 0.998 0.997 0.997 0.996 0.993 0.990
0.995 1.000 1.000 1.000 1.000 0.999 0.999 0.998 0.998 0.997 0.995
*Very high test specificity cannot always be achieved realistically since many inexpensive screening tests are not highly specific. For a low disease prevalence of around 1% (0.01), 
if the highest specificity achievable is 95%, then the sensitivity in the control group would have to be lowered to <5% in order for the test configuration to have a TAP of 1. Such 
extremes would be undesirable.
Figure 6. Relationship between test sensitivity, positive predictive 
value, and Test to Actual Positives (TAP) ratio.
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Alternatively, substituting the expression 
for TAP given in [5],
[9] P = [T-(1-Sp)]/(Se+Sp-1)
Thus, this equation can be applied to cor-
rect the inaccuracy of any test with known 
sensitivity and specificity (14). For example, 
suppose that we want to survey a population 
and we assume that the disease prevalence 
will be around 20%. Further suppose that a 
standard screening test has been used exten-
sively and has properties in the target popula-
tion which are known (sensitivity of 90% and 
specificity of 80%). When the true prevalence 
is 20%, the standard test configuration would 
be expected to label 34% of the population as 
positive, a serious overestimate of the true dis-
ease prevalence. If the true prevalence is 10%, 
the standard test configuration would yield a 
27% test-positive prevalence, a serious over-
estimate. These could be corrected with the 
above equation to obtain the corrected value 
of 20% and 10%, respectively.
This direct correction can eliminate bias 
irrespective of the true (but unknown) dis-
ease prevalence. In addition, standard statis-
tical inference procedures can be applied to 
compute confidence intervals (assuming that 
Se and Sp are fixed known parameters). Even 
when the test sensitivity and specificity are 
not known precisely in the study population, 
direct correction estimates may typically be 
more accurate than those without correction. 
However, this may not necessarily be the case 
and examples of problems with direct correc-
tion have been published (25,26). To improve 
the validity of this approach a validation sub-
study could be carried out in the target pop-
ulation and this could take place concurrent-
ly with the main study. This direct correction 
approach is essentially a two-stage design, with 
relatively straight-forward statistical inference. 
The main study and substudy could be com-
bined and analyzed together via maximum 
likelihood methods, thus yielding valid esti-
mates for disease prevalence, as well as sensitiv-
ity and specificity of the test. This can give esti-
mates with confidence intervals (11,27).
Corrections could be applied in different 
exposure cohorts and within strata; if Se and 
Sp are the same in all groups, then this is non-
differential disease misclassification; if they 
vary across groups, then this is differential mis-
classification. Results of repeated corrections 
with different estimates of Se and Sp could be 
tabulated to give a sensitivity analysis.
If the validation standard is measured with 
error, then the corrected error will be biased. 
Any bias in the corrected estimate will be less 
than that in the uncorrected estimate, if the 
Se and Sp of the validation measure is higher 
than that of the regular measurement. Howev-
er, it is better to have a sensitivity analysis with 
formal correction methods even when inter-
nal validation methods are available (28,29). 
Correction methods, which are more efficient 
and more general, can be obtained using likeli-
hood-based approaches (27).
Influence of the TAP ratio on the power of a 
randomized controlled trials
Disease episodes defined by diagnostic test re-
sults are commonly measured in controlled 
trials. Measurement error theory suggests that 
the higher the misclassification of the out-
come, the lower the power to detect differenc-
es across groups. Consider a trial in a popula-
tion in which the disease prevalence is known 
to be 5% from previous studies and in which 
the test used has been shown to have a sensitiv-
ity of 80% and specificity of 95%. Assume also 
that the trial includes 5000 participants per 
group, with a targeted reduction in outcome 
events due to the intervention from 250/5000 
episodes (0.05) to 125/5000 episodes (0.025) 
over the study period. If the intervention 
group had 125 actual cases, it would be mea-
sured as 344 positive tests in the study cohort; 
analogously, 250 actual cases of disease in the 
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control group would be measured as 438 posi-
tive tests. Instead of a reduction of 50% in in-
cidence (125 vs 250 cases) due to the inter-
vention, it will appear that a reduction of only 
22% has been achieved (344 vs 438 cases). This 
could result in an underestimation of the im-
pact of the intervention or even an incorrect 
conclusion that the intervention is ineffective 
due to inadequate power to reject the null hy-
pothesis.
In this example, Fisher exact test with α 
of 0.05 suggests that the sample size need-
ed for 80% power is N = 3312 per group (if a 
test with 80% sensitivity and 95% specificity is 
used).
In this case, the test would be expected to 
label 8.75% of the control group and 6.88% 
in the control group as positives (odds ra-
tio, 0.77, instead of the true 0.49). In con-
trast, the direct correction approach would 
still yield unbiased estimates of 5% and 2.5%, 
but the study would have needed thousands 
of subjects.
However, the TAP ratio approach could be 
used to reconfigure the test before the start of 
the trial. Ideally, this would involve configur-
ing and applying the test separately for control 
and intervention groups. Thus, for the con-
trol group, TAP = 1 implies that (1-Sp)/(1-
Se) should be equal to 0.0526; this could be 
achieved, for example, with sensitivity of 62% 
and specificity of 98%. In the intervention 
group, TAP = 1 implies that (1-Sp)/(1-Se) 
should be equal to 0.0256, and this could be 
achieved with for example a sensitivity of 22% 
and specificity of 98% or a sensitivity of 61% 
and specificity of 99%.
This approach could, in theory, result in 
the expected test positives equaling the true 
positives in each group (ie, 5% and 2.5%). If 
this were possible to achieve in practice, then 
in theory the required sample size would be 
N = 960 per group, if appropriate test configu-
rations (having TAP of 1) are used.
If there were good data (for example, from 
a validation substudy in the same population) 
to support the choice of the most appropriate 
test sensitivity and specificity, and if feasible in 
practice, using test configurations with TAPs 
close to unity would be advantageous from the 
viewpoint of efficiency. However, some uncer-
tainty would remain about test performance 
characteristics and therefore the extent of re-
maining bias.
Summarizing the limitations of the use of TAP 
ratio
We already stated that the primary aim of the 
use of TAP ratio is in situations where an esti-
mate of the prevalence or incidence of disease 
in a population is being made. However, there 
are some caveats, limitations, and special con-
siderations associated with its potential use to 
which we would like to point systematically 
in this section. For example, there will be sit-
uations when there are several screening test 
available for one diagnosis. In these cases, TAP 
ratio can be particularly helpful when deciding 
which one to apply in burden measure stud-
ies, because a combination of test sensitivity 
and specificity that renders it useful in clini-
cal setting may not be ideal for its application 
in community-based studies, where tests with 
different properties may do better. Further-
more, when the disease of interest is very rare, 
the effects of a decrease in test specificity on 
the TAP ratio at very low disease prevalence 
can be dramatic and a diagnostic test for dis-
ease burden estimates should only be used if 
positives can be checked and established with 
nearly 100% accuracy, which would allow cal-
culation of positive predictive value. When 
the disease is known to often be under-report-
ed, especially if this is due to lack of availabil-
ity of highly accurate screening test from clini-
cal settings, a consideration should be given to 
the possible use of cheaper or more efficient al-
ternative test strategies in circumstances where 
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resources are limited. This is because even if 
their sensitivity and specificity are very low, 
they may still do very well in estimating dis-
ease burden in the population, depending on 
disease prevalence.
Cost-effectiveness of use of TAP ratio 
should be very high, because it only takes a 
very limited sub-sample of positively tested 
cases to be verified at a secondary facility to es-
tablish positive predictive value. Once this pa-
rameter becomes available, there are no further 
costs in applying TAP ratio, and the expected 
benefits in terms of improving accuracy of the 
estimates and ensuring adequate power of the 
planned research study will outweigh the costs 
of the pilot study under large majority of as-
sumptions.
There are also some special circumstanc-
es that could limit the use of TAP ratio. One 
possible concern is how TAP ratio would ap-
ply to verbal autopsy data, given that all causes 
of death must add to 100%. If TAP was ap-
propriately applied to correct for each re-
ported cause individually, their proportions 
may change but they would still need to add 
to 100%. If such corrected cause-specific esti-
mates considerably exceed the overall number 
of recorded deaths after the correction using 
TAP is made, that would imply that the use 
of TAP ratio highlighted the problem of mul-
tiple causes leading to a single death (which is 
often the case). If they fall well below 100% of 
all recorded deaths when added up, that would 
imply that there are further causes of mortality 
that were not picked up by verbal autopsy tool 
(which is, again, often the case).
Theoretically, it may be possible that sen-
sitivity and specificity is different for the same 
instrument used in different settings. This 
consideration again justifies the use of a pilot-
study to establish all the necessary key param-
eters needed for the application of the TAP 
ratio. Finally, there will be cases when preva-
lence rate will be reported, but the screening 
procedure used will be unknown. In those cas-
es, contacting the authors of the study about 
the tool they used to establish the prevalence is 
the safest way to correct their estimate (if nec-
essary), as TAP ratio cannot be applied.
Discussion
In studies where the aim is to measure disease 
frequency in a population, a diagnostic test 
may be used to identify disease episodes when 
it is not possible to make a definitive diagnosis 
of the disease. This is typically the case in com-
munity-based studies (especially in resource 
poor settings, where access to hospitals or re-
search facilities may be poor), where disease 
prevalence is low and where resources do not 
permit highly trained staff to participate di-
rectly in the disease surveillance. To interpret 
the results of such studies, it is important to 
have information about the extent of misclas-
sification from the test. Misclassification itself 
does not inevitably result in inaccurate esti-
mates. It is the imbalance between the num-
ber of false positives and false negatives that 
creates inaccuracy (30). Somewhat counter-in-
tuitively, in some circumstances a decrease in 
sensitivity or specificity may actually result in 
more accurate estimates being reached (30).
Diagnostic test parameters are estimat-
ed typically in clinical settings and test speci-
fications are set to meet clinical requirements, 
where high sensitivity is often accorded rela-
tively higher priority than in epidemiological 
studies. The application of such test specifica-
tions to population-based epidemiological re-
search is problematic. First, as we illustrate, 
the differing test populations and settings can 
yield very different test performance, even 
when disease prevalence is constant. For clin-
ical pneumonia, the specificity of the WHO 
test in community-based clinical pneumo-
nia studies is very high (at least 95%), where-
as it has been repeatedly reported to be in the 
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range of 70%-80% in hospital out-patient 
studies (7,10). This is most likely to be because 
the study populations are quite different, with 
the majority of children being completely well 
(and with low respiratory rates) in the com-
munity-based studies, whereas most children 
are ill (with a variety of conditions other than 
clinical pneumonia that may tend to increase 
respiratory rate) in the hospital-based studies.
The relationship between test positives, 
positive predictive value, and true prevalence 
has been considered in a study of health in-
terview surveys. This study made suggestions 
on how to correct the apparent prevalence 
in a survey for shortcomings in the methods 
used to estimate them and to take into ac-
count their absolute values (14). The Aus-
tralian Institute of Health and Welfare used 
routine data to monitor the incidence of ma-
jor cardiovascular events in Australia and de-
rived corrected numerators by multiplying 
counts of events by sensitivity and dividing by 
the positive predictive value of clinical diag-
noses as judged against criteria developed for 
the World Health Organization MONICA 
Project (http://www.health.nsw.gov.au/pub-
lic-health/chorep/cvd/cvd_intro.htm). How-
ever, adjustment for misclassification bias has 
proven unsuccessful when information from 
an appropriate study population has not been 
available or applied incorrectly (26,31). An ex-
ample of this are verbal autopsy studies, which 
are commonly used to define causes of death 
in disease burden studies in developing coun-
tries and which form an important part of the 
evidence base of global burden of disease es-
timates. These studies have often taken sen-
sitivity and specificity estimates from study 
populations with substantially different pat-
terns of cause-specific mortality (25) and this 
has led to incorrect conclusions being reached 
from the data. Second, optimal test character-
istics for use in a population-based survey are 
likely to be different from those when the test 
is used in a clinical setting. In the example of 
community-based studies reporting clini-
cal pneumonia incidence in young children, 
the respiratory rate threshold for the defini-
tion of clinical pneumonia was lowered by 
WHO from 50 breaths per minute or above 
to 40 in children 1-4 years of age. This revised 
test specification, which has higher sensitiv-
ity but lower specificity for clinical pneumo-
nia, was introduced so that an increased per-
centage of children with clinical pneumonia 
would be identified and treated appropriately. 
Although this change has benefits for clinical 
practice, the revised test specification will re-
sult in less accurate overall clinical pneumonia 
frequency estimates when used in disease bur-
den studies, as lower test specificity at low dis-
ease prevalence will inflate estimates of clinical 
pneumonia incidence (32-34).
However, by understanding the relation-
ship between sensitivity, specificity, and dis-
ease prevalence the TAP ratio can be calculat-
ed. We suggest that the TAP ratio is the most 
useful summary measure of the potential for 
disease misclassification bias. In some studies it 
may be possible to estimate test sensitivity and 
specificity for various test configurations and 
use these data to set the test specification to 
result in roughly equivalent numbers of false 
positives and false negatives. This may improve 
study efficiency and is still compatible with 
later direct correction of the final estimates. It 
is important to note that improving test sen-
sitivity and specificity alone may not improve 
the accuracy of disease frequency estimates.
In studies in which the TAP ratio shows a 
large potential for bias it is important to con-
sider the implications for study design and to 
plan to apply a direct correction approach (see 
equation 9). In surveys measuring rare disease 
events or in regular surveillance of common 
disease events, such that events are rare in each 
survey, the potential for over-estimation is 
high. It is particularly important to maximize 
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test specificity and advisable to check a sample 
of test positives (to estimate the test positive 
predictive value) to assess the level of possible 
over-estimation (as described above). An alter-
native strategy would be to avoid application 
of the test in settings of very low disease prev-
alence, since the TAP ratio may be markedly 
different from 1.0.
In practice, test sensitivity and specificity 
information over a range of test specifications 
is often not available. In these circumstances 
it may be possible to estimate a plausible range 
for the TAP ratio. One example, when disease 
prevalence is low, would be to check the valid-
ity of all or a sample of test positives to mea-
sure the test positive predictive value. Limits 
within which the TAP ratio must lie can then 
be defined over a range of plausible test sensi-
tivity values.
When a diagnostic test result is used to de-
fine outcome events in a controlled trial, then 
test misclassification has important implica-
tions for the power of the trial and for the es-
timation of the size of difference in disease fre-
quency in intervention groups (34,35). We 
have suggested a use for the TAP ratio by cali-
brating the test a priori to bring it closer to a 
TAP of unity. This would realize certain effi-
ciency benefits. Then, at the end of the study, 
one could still apply the appropriate direct 
correction (equation 9) to eliminate the re-
maining bias (due to the test configuration not 
being entirely appropriate because of missed 
assumptions).
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